Overview * Sweden life science supplier's Q2 net sales rose 6% yr/yr, beating analyst expectations * Q2 EBITA up 11% and margin improved to 12.6% * Company says recent acquisitions contributed to
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)